Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HORIZON: GSK4532990 in Adults With Nonalcoholic Steatohepatitis
NCT05583344Phase 2Active, not recruiting
- Sponsor
- GSK
- Start
- Jan 2023
- Primary completion
- Jan 2026
- Modality
- Conjugated siRNA, Peptide-Drug Conjugates, Chemically Modified siRNA
- Countries
- 17
01
Overview
A Phase 2 trial of GSK4532990 in Nonalcoholic steatohepatitis (NASH), sponsored by GSK. Started Jan 2023; status: active, not recruiting.
02
Drugs
GSK4532990
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT05583344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05583344.